Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2022

09-08-2022 | Lymphoma | Letter to the Editor

Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type

Authors: Satoko Oka, Kazuo Ono, Masaharu Nohgawa

Published in: Annals of Hematology | Issue 10/2022

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Senff NJ, Noordijk EM, Kim YH et al (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112(5):1600–1609CrossRef
2.
Di Raimondo C, Abdulla FR, Zain J et al (2019) Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol 187(3):e79–e82CrossRef
3.
Pang A, Au-Yeung R, Leung RYY et al (2019) Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib. Ann Hematol 98(10):2433–2436CrossRef
4.
Beylot-Barry M, Mermin D, Maillard A et al (2018) A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol 138(9):1982–1989CrossRef
5.
Sehn LH, Hertzberg M, Opat S et al (2022) Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 6(2):533–543CrossRef
6.
Maurer MJ, Ghesquières H, Jais JP et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32(10):1066–1073CrossRef
7.
Xu-Monette ZY, Tu M, Jabbar KJ et al (2015) Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 6(8):5615–5633CrossRef
Metadata
Title
Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type
Authors
Satoko Oka
Kazuo Ono
Masaharu Nohgawa
Publication date
09-08-2022

Other articles of this Issue 10/2022

Annals of Hematology 10/2022 Go to the issue

Original Article

Prognostic value and computer image analysis of p53 in mantle cell lymphoma

Letter to the Editor

First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia

Original Article

Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review

Letter to the Editor

Prognostic impact of switching from cyclosporine to corticosteroids early after single cord blood transplantation

Letter to the Editor

Can we restart the rituximab after remission of rituximab-induced interstitial lung disease in malignant lymphoma?

Letter to the Editor

Non-traumatic splenic rupture after discontinuation of zanubrutinib and venetoclax therapy in relapsed/refractory diffuse large B-cell lymphoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits